Beidh Ceolchoirm am lóin ar siúl ar an Luan, 5 Nollaig, ón 1-2i.n. i dTéatar Uí Chearbhalláin in Áras na Gaeilge in OÉ Gaillimh. Is mic léinn ón gcúrsa Dioplóma sna Dána: Cóiriú agus Stáitsiú an Cheoil Thraidisiúnta a chuirfidh an ceolchoirm speisialta seo i láthair.  Tá an cúrsa á reáchtáil sa Spidéal ag Acadamh na hOllscolaíochta Gaeilge i gcomhar le Stiúideo Cuan. Meascán spéisiúil a bheas ann a chlúdóidh réimse leathan ceoil, idir seoidíní traidisiúnta, ceol nua-chumtha, amhránaíocht agus, dár ndóigh, ríleanna, poirt agus pólcaí spleodracha, spraoiúla.   Is ó chian agus ó chóngar a tháinig na ceoltóirí agus na hamhránaithe seo le chéile mar aon ghrúpa amháin agus dá réir snítear tionchair agus stíleanna éagsúla lena chéile ina gcuid ceoil. Tá roinnt mhaith ceolchoirmeacha déanta acu mar ghrúpa. Ó thosaigh siad le chéile i mí Meán Fómhair i mbliana rinne siad ceolchoirm lóin in Acadamh na hOllscolaíochta Gaeilge ar an gCeathrú Rua agus i seanscoil Shailearna. Ní le ceol amháin a bhíonn siad ag plé ar an gcúrsa seo, áfach, mar go mbíonn siad ag tabhairt faoi ghnéithe teicniúla an cheoil chomh maith. Chuige sin rinne siad clár raidió a thaifead sa stiúideo.  Is é Seán Ó Flatharta, Oifigeach Teanga agus Cultúir, OÉ Gaillimh, atá ag eagrú na hocáide seo i gcomhar le Marianne Ní Chinnéide, Riarthóir Aonad na dTaibhealaíon.  Ní bheidh aon táille ar an doras. Tuilleadh eolais le fáil ó: Marianne Ní Chinnéide, Acadamh na hOllscolaíochta Gaeilge, OÉ Gaillimh ag 087 9080194 nó marianne.nichinneide@oegaillimh.ie, nó Seán Ó Flatharta, Oifigeach Teanga agus Cultúir, ag 091 493518 nó s.oflatharta2@nuigalway.ie. -Críoch-

A new clinical study has opened in Ireland for a rare but devastating type of bone marrow cancer. Irish patients with advanced myelofibrosis will have access to a new study of combined oral medications for their disease.  Frank Giles, Professor of Cancer Therapeutics at NUI Galway and Trinity College Dublin, is leading the study with Eibhlin Conneally, Consultant Haematologist at St James’s Hospital, Dublin. The Irish study is being run in conjunction with centers in France, Italy, and the UK and patients may be enrolled at either Galway University Hospitals or St James’s Hospital.  The study involves a combination of Ruxolitinib, manufactured by Novartis, along with another pill that also targets the abnormal pathways that drive myelofibrosis. This news comes within weeks of Ruxolitinib becoming the first and only product approved for this disease by the US Food and Drug Administration (FDA).  Myelofibrosis is a life-threatening cancer of the bone marrow that results in bone marrow failure because the normal spaces in which blood cells are formed become progressively filled with fibrous tissue. In an attempt to maintain normal blood cell counts, the body then begins to make these cells in abnormal sites including the liver and spleen. In turn, these can then become enlarged and painful. Patients not alone are at risk from marrow failure, but in some patients, myelofibrosis changes into a particularly aggressive form of acute leukemia.  According to Professor Frank Giles, who is also Director of the HRB Clinical Research Facility Galway, a joint venture between Galway University Hospitals and NUI Galway: “We are delighted to finally have our first effective therapy for patients suffering from advanced myelofibrosis. This is a significant positive advance in treatment for these patients. We are very pleased to be able to offer this study to patients here in Ireland, especially as Ruxolitinib has just been approved in the US. We hope that approval in Europe will happen soon but in the interim we have an opportunity to build on this, our first broadly effective therapy for a very debilitating illness, and hopefully offer even better therapy with a combination of medications in the near future.” Ruxolitinib is specifically directed at an abnormally active enzyme or kinase that has been recently defined as a key driver of myelofibrosis. “This kinase, called Jak-2, has emerged as a key target for therapy in myelofibrosis”, said Dr Conneally. “It is a central driver of the disease and inhibiting its function with Ruxolitinib directly improves many patients’ symptoms and reduces their spleen swelling. It is the latest big success in our move away from non-specific cell-killing drugs towards safer, more targeted drugs that are really directed at the fundamental drivers of cancer.” Professor Giles, who has been involved with the development of both of the drugs  being combined in the study, said: “Success in anti-cancer therapies are increasingly driven by a continuous process which involves pre-clinical scientists unlocking the puzzles of what actually makes a cancer cell behave differently from its normal counterpart. Once you have mapped the cancer process, you can define a cancer cell’s key vulnerabilities which leads you to relatively selective targets. Next steps are the creation and testing of drugs or other approaches directed at these targets that will  alter cancer cell behaviour in terms of either killing it or forcing it to behave more like a normal cell. Once these approaches are available to our patients, we return to pre-clinical science to refine and improve anti-cancer therapy, for example, by combining agents with different targets as we are doing on this study.” He concluded: This ‘bench-to-bedside-to-bench’ process has allowed not only the development of Ruxolitinib but allowed us to develop logical ‘next-wave’ potential therapies for patients with myelofibrosis. Collaborations over the last decade between scientists around the world have led to Ruxolitinib being available. Collaborations within Ireland and with our European colleagues have allowed us to offer this study in such a timely manner to Irish patients – a very encouraging template for future success.” -ends-

The 2011 Galway Science and Technology Festival Exhibition, part of Discover Science’s National Science Week, was held on the NUI Galway campus last Sunday and attracted 24,000 visitors. The event was officially opened by the European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn and guest speakers included Dr James Browne, President of NUI Galway, Mayor of Galway City Cllr Hildegarde Naughton and Mr Tom Hyland, Festival Chairman. The European Commissioner commented, “It is a great pleasure for me to welcome everyone to the 2011 Galway Science & Technology Festival Exhibition. The foundation and nurtuing of this festival took vision and dedication and its existence is thanks to the vision of Noel Treacey whose brain-child it is. His work and that of strong supporters like Dr Jim Browne and Tom Hyland as well as many of the companies, educational institutes and researchers, have made this a festival of which to be very proud. For the past two weeks over thousands of young people have taken part in the Festival and engaged with scientists and researchers, asking questions and really getting in touch with science and technology. These young people are the scientists and innovators of tomorrow, and events like this festival are very important in stimulating their curiousity. As a former teacher, I know very well the importance of capturing a child’s imagination at an early age. This is especially important in the case of science and technology, since they pervade almost every aspect of modern life. In today’s economic climate it is more important than ever to ensure that young people are equipped with the skills that they need to succeed. And we need science and technology to get our economy back on track.” The event ran extremely well with up to 100 volunteers, which included students from the Dominican College Secondary School, NUI Galway and members of the public, who provided information and directions to families attending the 80 interactive exhibition stands and the various shows and workshops throughout the University campus. Families and children enjoyed an array of colourful stands including Medtronic who demonstrated how blood pumps around the body, Boston Scientific’s amazing stand with a large stent for children to examine, SAP provided a First Lego League, Hewlett Packard with the help of sixth class students from Briarhill School explained Cloud Computing while other amazing stands were hosted by CISCO, Covidien Avaya and Lake Region. The Galway Enterprise Board stand included local company Starlight and a new App “Ireland: Are we there Yet” by local developer Ann Brehony.  The stands allowed children and adults alike to participate in experiments, watch demonstrations and discuss ideas with researchers. Lots more interatactive exhibitions took place from NUI Galway, GMIT, Marine Institute and many more. A lego competition sponsored by Smyth’s Toys Superstore was in huge demand and accommodated over 300 eager technic lego builders while the 5ft tall Buzz Light Year made of Lego was on loan from Smyth’s for the day was a huge hit with hundreds of children. Sue McGrath’s Chemistry Show was seen by 1,000 people, the Mad Scientist entertained and excited young children about science while Robert Hill explained the Outerworld in his own amazing and engaging way. The RCX Mindstorm lego workshop was in huge demand and Magic Mathworks demonstrated a great way of engaging with maths.  Kitchen Chemistry ran shows throughout the day and educated visitors on how to conduct experiments in the kitchen using regular household products while Bubble Magic had the audience screaming with excitement creating huge bubbles and filling them with smoke. One of the major successes of the Exhibition was a total of 18 Primary and Secondary Schools encompassing 350 students exhibiting their own brilliant science and technology projects while many other students took part by participating with the international companies and helped them demonstrate their products. The opportunity for these young people to attend and work at the Exhibition and engage with the public is of enormous experience for them. Festival Chairman, Tom Hyland commented, “Special thanks must go to the Volunteers who helped in running the event so smoothly and allowing families enjoy their day out. The prebooking system of shows worked wonderfully and really helped people plan their day and those without tickets were also accommodated. I would also like to take this opportunity to thank our main sponsor Medtronic and all other sponsors and the multi-national companies who have agreed to take part in our Mentoring Program where 11 different companies participating in this initiative will visit schools over the next few months and talk to the students about their subject choices, give practical career advice and share their work experience. I would also like to thank NUI Galway for providing the campus facilities to host this truly wonderful event.” Mr Hyland also presented special awards on behalf of the Festival Committee to Brother Niall of the Patrician Brothers with the 2011 Galway Science & Technology Person of the Year Award for his commitment to the Festival over the 14 years and an award to 12-year old sixth class whizz kid Harry Moran from Westport on becoming the world’s youngest app developer of Pizzabot based on a pizza shooting red sauce at slices of salami which he developed in one month. Visit www.galwayscience.ie to view some of the photos and videos captured during the Festival Exhibition.ends

Come rain or shine, a new website showing the current weather conditions in Galway is now available to the general public. The site uses real-time data collected by a weather station at NUI Galway to show temperature, humidity, pressure, wind, rain and sunshine.   Behind the project is the Informatics Research Unit for Sustainable Energy (IRUSE) at NUI Galway, under the leadership of Dr Marcus Keane. IRUSE focuses on achieving the goal of energy efficient buildings. In order to support ongoing and future research activity, IRUSE installed an automated weather station at NUI Galway.   Information from the weather station now appears in real-time on a website http://weather.nuigalway.ie/ thanks to students of the HDip / MSc in Software Design and Development. Colin Divily from Corofin, Co Galway and Naomi Ono, originally from Japan, implemented the website through a collaboration with the Discipline of Information Technology. They were supported by Johann Ott, Magdalena Hajdukiewicz and other members of the IRUSE group.   Dr Marcus Keane explains: “The website displays the live weather data, as well as 12-hour and monthly trends and provides essential data for the research carried out at the University. With the weather being such a constant topic of conversation for everyone in this country, we thought it only right to share this data with the general public.”   The weather station was installed in June 2010 on the roof of the Concourse building on campus. The data loads to the new website every minute from all of the sensors, except for rainfall which is reported hourly.   As well as for IRUSE’s research, the weather station is also used as part of teaching for the Energy Systems Engineering degree programme at NUI Galway.   -ends-

BioInnovate Ireland is now seeking Expressions of Interest for its medical device innovation Fellowship programme. This programme is modelled on the prestigious and internationally-recognised Biodesign programme offered at Stanford University, California.  The recruitment of eight Fellows to work in two elite multidisciplinary teams is now underway. These two teams will focus on a specific clinical area, identifying unmet needs, inventing solutions to meet those needs and implementing the solutions, and mapping a route to commercialisation to enable these solutions to enhance patient care. The Fellowship teams will complete an intensive five week training period, commencing in August 2012, before spending two months of clinical immersion working with top surgeons and medical staff in numerous hospitals around Ireland. The Fellowship teams will then focus on inventing and implementing solutions to address specific problems for the remainder of this 10 month programme. According to BioInnovate Ireland Programme Director, Dr Mark Bruzzi from NUI Galway: “The BioInnovate Ireland Programme offers a unique opportunity for individuals to come together to work in teams to develop novel solutions that impact patient care, and gain access to a network of industry, academic and clinical leaders to guide their solutions from concept to commercialisation.” The Fellowship Programme is full-time, stipend supported and the next programme will commence on 1 August, 2012. In addition to the Fellowship Programme, there are two BioInnovate classes open to postgraduate students of the BioInnovate Academic Partners which include NUI Galway, University of Limerick, Dublin City University, Royal College of Surgeons Ireland and University College Cork.  The BioInnovate class will be mentored by, and work with the Fellows on the newly identified clinical needs.  Marie Travers, a current Galway BioInnovate Fellow, said: “The experience so far is exciting. I feel very privileged to have been able to access experts, patients and clinicians as part of the research. I see great potential for identifying innovations for patient care.” The BioInnovate Fellowship teams are multi-disciplinary and eligible applicants should have a background in medicine, engineering, technology or business. Applicants with a postgraduate degree or relevant professional experience are particularly welcome.  Medical and surgical registrars or specialist registrars with an interest in innovation and improving patient care through technological advancements are also encouraged to apply for the Fellowship. Candidates will be assessed for their leadership potential, interest in technology innovation, demonstrated potential for creativity and invention, and ability to work in a team. For an Expression of Interest form or further details contact Clodagh Barry, BioInnovate Programme Manager at NUI Galway, on 091 494212 or clodagh.barry@nuigalway.ie                                                                                                                                                                                                                                              -ENDS-